MEENAKSHI ANURAG to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications MEENAKSHI ANURAG has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.260
-
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605.
Score: 0.112
-
CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree? Clin Cancer Res. 2020 01 01; 26(1):3-5.
Score: 0.091
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 03 01; 10(3):362-371.
Score: 0.031
-
Immunogenomic?profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Res Treat. 2021 Aug; 189(1):187-202.
Score: 0.026